A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
A Phase II Study of JS212 Monotherapy or Combination Therapy With JS207 or JS001 in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
研究概览
地位
条件
详细说明
The study consists of 2 parts. Both parts consist of safety run-in period and cohort expansion period. Safety run-in period will enroll those who have received only 1 line of prior systemic standard treatment. Cohort expansion period will enroll those are treated naive or recived treatment in adjuvant phase.
Part 1 will receive JS212 monotherapy or combination therapy with JS207, based on the PD-L1 expression. Part 2 will receive JS212 in combination with JS001.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Chaoqiang Yang, PM
- 电话号码:18252095266
- 邮箱:chaoqiang_yang@junshipharma.com
学习地点
-
-
-
Beijing、中国
- 招聘中
- Peking University People's Hospital
-
接触:
- Shu Wang, PhD.
- 电话号码:13801080201
- 邮箱:dr.wangshu@263.net
-
首席研究员:
- Shu Wang, Ph.D.
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100144
- 尚未招聘
- Peking University Shougang Hospital
-
接触:
- Xueli Mo, Master
- 电话号码:13699180225
- 邮箱:xuelimo@hotmail.com
-
首席研究员:
- Xueli Mo, Master
-
Beijing、Beijing Municipality、中国、100071
- 尚未招聘
- The Fifth Medical Center of Chinese PLA General Hospital
-
接触:
- Shaohua Zhang, Doctor
- 电话号码:13311591557
- 邮箱:zhangsh19760428@163.com
-
首席研究员:
- Shaohua Zhang, Doctor
-
-
Fujian
-
Fuzhou、Fujian、中国、350000
- 尚未招聘
- Fujian Cancer Hospital
-
接触:
- Fan Wu, Ph.D.
- 电话号码:13859082118
- 邮箱:wufan_fj@163.com
-
首席研究员:
- Fan Wu, Ph.D.
-
-
Gansu
-
Lanzhou、Gansu、中国、730000
- 尚未招聘
- The First Hospital of Lanzhou University
-
接触:
- Xiaoling Ling, Ph.D.
- 电话号码:18693165668
- 邮箱:lingxiaolingedu@163.com
-
首席研究员:
- Xiaoling Ling, Ph.D.
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- 尚未招聘
- Sun Yat-sen University Cancer Center
-
接触:
- Shusen Wang, Ph.D.
- 电话号码:13926168469
- 邮箱:wangshs2019@163.com
-
首席研究员:
- Shusen Wang, Ph.D.
-
Guangzhou、Guangdong、中国、510080
- 尚未招聘
- Guangdong General Hospital
-
接触:
- Kun Wang, Ph.D.
- 电话号码:13922118086
- 邮箱:bzwangkun@163.com
-
首席研究员:
- Kun Wang, Ph.D.
-
-
Guizhou
-
Guiyang、Guizhou、中国、550004
- 尚未招聘
- The Affiliated Hospital of Guizhou Medical University
-
接触:
- Shu Liu, Ph.D.
- 电话号码:13908516963
- 邮箱:drliushu@163.com
-
首席研究员:
- Shu Liu, Ph.D.
-
Guiyang、Guizhou、中国、550001
- 尚未招聘
- The Affiliated Cancer Hospital of Guizhou Medical University City: Guiyang
-
接触:
- Zhihong Wang, Bachelor
- 电话号码:13595159308
- 邮箱:Wzh1968626@sina.com
-
首席研究员:
- Zhihong Wang, Bachelor
-
-
Hebei
-
Baoding、Hebei、中国、071000
- 尚未招聘
- Affiliated Hospital of Hebei University
-
接触:
- Hua Yang, Ph.D.
- 电话号码:18603120729
- 邮箱:docyh@163.com
-
首席研究员:
- Hua Yang, Ph.D.
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150081
- 尚未招聘
- Harbin Medical University Cancer Hospital
-
接触:
- Wenhui Zhao, Ph.D.
- 电话号码:18745177632
- 邮箱:zhaowenhui1977@163.com
-
首席研究员:
- Wenhui Zhao, Ph.D.
-
-
Henan
-
Zhengzhou、Henan、中国、450001
- 尚未招聘
- The First Affiliated Hospital of Zhengzhou University
-
接触:
- Hong Zong, Ph.D.
- 电话号码:13623586882
- 邮箱:zonghong522@126.com
-
首席研究员:
- Hong Zong, Ph.D.
-
Zhengzhou、Henan、中国、450002
- 尚未招聘
- Henan Cancer Hospital
-
接触:
- Min Yan, Ph.D.
- 电话号码:15713857388
- 邮箱:ym200678@126.com
-
首席研究员:
- Min Yan, Ph.D.
-
-
Hubei
-
Wuhan、Hubei、中国、430079
- 尚未招聘
- Hubei Cancer Hospital
-
接触:
- Xinhong Wu, Ph.D.
- 电话号码:18602726300
- 邮箱:Xinhongwuhbch@163.com
-
首席研究员:
- Xinhong Wu, Ph.D.
-
-
Hunan
-
Changde、Hunan、中国、415003
- 尚未招聘
- The First People's Hospital of Changde City
-
接触:
- Hui Li, Ph.D.
- 电话号码:15886648808
- 邮箱:373099626@qq.com
-
首席研究员:
- Hui Li, Ph.D.
-
Changsha、Hunan、中国、410013
- 尚未招聘
- Hunan Cancer Hospital
-
接触:
- Quchang Ouyang, Ph.D.
- 电话号码:13973135318
- 邮箱:oyqc1969@126.com
-
首席研究员:
- Quchang Ouyang, Ph.D.
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- 尚未招聘
- Jiangsu Province Hospital
-
接触:
- Wei Li, Ph.D.
- 电话号码:13851603656
- 邮箱:real.lw@163.com
-
首席研究员:
- Wei Li, Ph.D.
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330009
- 尚未招聘
- Nanchang People's Hospital
-
接触:
- Wenyan Chen, Bachelor
- 电话号码:18679168977
- 邮箱:chenwenyannc2013@163.com
-
首席研究员:
- Wenyan Chen, Bachelor
-
-
Jilin
-
Changchun、Jilin、中国、130021
- 尚未招聘
- The First Hospital of Jilin University
-
接触:
- Lihua Kang, Ph.D.
- 电话号码:13504334518
- 邮箱:kanglihua961002@163.com
-
首席研究员:
- Lihua Kang, Ph.D.
-
Changchun、Jilin、中国、130012
- 尚未招聘
- Jilin Provincial Cancer Hospital
-
接触:
- Fei Chen, Master
- 电话号码:18604430968
- 邮箱:Email:flyrcf@163.com
-
首席研究员:
- Fei Chen, Master
-
-
Liaoning
-
Shenyang、Liaoning、中国、110022
- 尚未招聘
- Shengjing Hospital of China Medical University
-
接触:
- Xihe Zhao, Ph.D.
- 电话号码:18940259508
- 邮箱:zhaoxh@sj-hospital.org
-
首席研究员:
- Xihe Zhao, Ph.D.
-
Shenyang、Liaoning、中国、110042
- 尚未招聘
- Cancer Hospital of Dalian University of Technology(Liaoning Cancer Hospital & Institute)
-
接触:
- Tao Sun, Ph.D.
- 电话号码:13940404526
- 邮箱:lnzlrxnsy@163.com
-
首席研究员:
- Tao Sun, Ph.D.
-
Shenyang、Liaoning、中国、110167
- 尚未招聘
- Introduction to the First Affiliated Hospital of China Medical University
-
接触:
- Yuee Teng, Ph.D.
- 电话号码:13591639797
- 邮箱:tengyuee517@yahoo.com.cn
-
首席研究员:
- Yuee Teng, Ph.D.
-
-
Ningxia
-
Yinchuan、Ningxia、中国、750000
- 尚未招聘
- General Hospital of Ningxia Medical University
-
接触:
- Ye Lv, Bachelor
- 电话号码:18709515757
- 邮箱:liuweilvye@yeah.net
-
首席研究员:
- Ye Lv, Bachelor
-
-
Shandong
-
Jinan、Shandong、中国、250117
- 尚未招聘
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
-
接触:
- Qi Dang, Master
- 电话号码:15318816098
- 邮箱:dangqi123456@126.com
-
接触:
- Huihui Li, Ph.D.
- 电话号码:15553103209
- 邮箱:15553103209@163.com
-
首席研究员:
- Huihui Li, Ph.D.
-
Jining、Shandong、中国、272000
- 尚未招聘
- Affiliated Hospital of Jining Medical University
-
接触:
- Changping Shan, Master
- 电话号码:18678766865
- 邮箱:scp9933@163.com
-
首席研究员:
- Changping Shan, Master
-
Qingdao、Shandong、中国、266000
- 尚未招聘
- The Affiliated Hospital of Qingdao University
-
接触:
- Haibo Wang, Ph.D.
- 电话号码:18661805787
- 邮箱:hbwangqy@126.com
-
首席研究员:
- Haibo Wang, Ph.D.
-
Weifang、Shandong、中国、261000
- 尚未招聘
- Weifang People's Hospital
-
接触:
- Wenhui Wang, Ph.D.
- 电话号码:18605368857
- 邮箱:wwh8857@163.com
-
首席研究员:
- Wenhui Wang, Ph.D.
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030013
- 尚未招聘
- Shanxi Cancer Hospital
-
接触:
- Guohui Han, Ph.D.
- 电话号码:13754858188
- 邮箱:13754858188@163.com
-
首席研究员:
- Guohui Han, Ph.D.
-
-
Sichuan
-
Chengdu、Sichuan、中国、610072
- 尚未招聘
- Sichuan Provincial People's Hospital
-
接触:
- Jing Luo, Ph.D.
- 电话号码:18981838521
- 邮箱:jingluopi@163.com
-
首席研究员:
- Jing Luo, Ph.D.
-
Mianyang、Sichuan、中国
- 尚未招聘
- Mianyang Central Hospital
-
接触:
- Zhen zhang, Master
- 电话号码:13778159530
- 邮箱:jiangzhangtong@sina.com
-
首席研究员:
- Zhen Zhang, Master
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female age 18-70 years old;
- Voluntary participation in clinical study;
- Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
- No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC;
- Adequate organ function;
- ECOG performance status of 0 or 1;
- Life expectancy 12 weeks;
- Measurable disease, as defined by RECIST v1.1;
Exclusion Criteria:
- Untreated or active central nervous system (CNS) metastases;
- Uncontrolled pleural effusion, pericardial effusion or ascites;
- Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage;
- History of significant bleeding tendency or severe coagulation disorder;
- Uncontrolled hypertension;
- Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose;
- History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period;
- History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C;
- Severe cardiovascular disease;
- Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug;
- Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;
- History of another malignancy within 5 years before the first dose of study drug;
- Not suitable to receive study treatment for other conditions as per investigator;
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort A
JS212 in combination with JS207,CPS≥10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
实验性的:Cohort B
JS212 monotherapy, CPS<10 |
JS212 will be administered intravenously on D1,Q3W |
|
实验性的:Cohort C
JS212 in combination with JS207, CPS<10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
实验性的:Cohort D
JS212 in combination with JS001 |
JS212 and JS001 will be administered intravenously on D1, Q3W |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective response rate(ORR)
大体时间:24 months
|
Objective response rate(ORR) evaluated based on RECIST v1.1 |
24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duration of response (DoR)
大体时间:24 months
|
Duration of response (DoR) evaluated based on RECIST v1.1 |
24 months
|
|
Disease control rate (DOR)
大体时间:24 months
|
Disease control rate (DOR)evaluated based on RECIST v1.1 |
24 months
|
|
Progression free survival (PFS)
大体时间:24 months
|
Progression free survival (PFS) evaluated based on RECIST v1.1 |
24 months
|
|
Overall Survival (OS)
大体时间:36 months
|
Overall Survival (OS)evaluated based on RECIST v1.1 |
36 months
|
|
Adverse Events
大体时间:24 months
|
Incidence and severity of Adverse Events(AEs)according to NCI-CTCAE v6.0 |
24 months
|
|
Immunogenicity
大体时间:24 months
|
The incidence of Nab(if applicable) of JS212 and JS207 |
24 months
|
|
Plasma concentrations
大体时间:2 years
|
Plasma concentrations of JS207 and 9MW2821 |
2 years
|
|
PD-L1 expression
大体时间:2 years
|
The correlation between PD-L1 expression in tumor tissue and therapeutic efficacy |
2 years
|
|
EGFR/HER expression
大体时间:2 years
|
The correlation between EGFR/HER3 expression in tumor tissue and therapeutic efficacy |
2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.